Structural Modifications on Natural-based Products: Synthetic Strategies and Biological Applications by Fonseca, André et al.
Structural Modifications on Natural-based Products: Synthetic 
Strategies and Biological Applications 
André Fonseca
a,b*













 and Eugenio Uriarte
b
 
a CIQUP/Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 4169-007 Porto, 
Portugal 
b Departamento de Química Orgánica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 
Santiago de Compostela, Spain 
c Departmento de Farmacologia, CIMUS, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, 
Spain 




Abstract Coumarins are a class of heterocyclic compounds present in a significant 
quantity in several plants. The simplest coumarin, a benzene ring fused with a pyran-2-
one heterocycle, was first discovered in the 19
th
 century and since then, due to the 
synthetic accessibility and the biological properties of its derivatives, has been playing 
an important role in the Medicinal Chemistry field. In fact, coumarins have been 
previously described as anticancer, antiviral, anti-inflammatory, antimicrobial, 
enzymatic inhibitory and antioxidant agents. 
Another two interesting compounds found widely in nature are resveratrol derivatives 
and chalcones. Both families of compounds are known for having remarkable 
antioxidant activity, cardio- and neuroprotective effects, among other relevant 
biological properties. Therefore, we devised several synthetic strategies to incorporate 
these natural products in one compound, combining their potential as promising agents 
for the treatment of several illnesses.  
In our group, we have already synthesised multiple novel compounds incorporating into 
the coumarin scaffold the resveratrol or chalcones moieties with remarkable activities 
towards different pharmacological targets.
 
In this work, we continue exploiting this 
strategy by incorporating different linkers at coumarin position 3, thus giving us a wide 
range of possibilities for new compounds. 
 
Keywords: Natural products, coumarins, resveratrol, chalcones, pharmacological 
applications.  
Introduction 
Before modern medicine, extracts of plants or plants itself were consumed for their 
medicinal properties in spite of lack of knowledge of its components or active 
compound. Nevertheless, we always relied on natural sources to cure ailments and 
diseases, and the study of natural extracts yielded a vast number of commercial 
available drugs, just by isolating a pharmacologically active compound or by 
synthesising an active compound through inspiration of a natural product structure.
[1]
 
Today we are facing changing demographics, the extension of life expansion lead to a 
growing number of cases of neurodegenerative diseases. Thus, there is always a need 
for a new drug that is safe and can ameliorate the symptoms or even treat these diseases. 
Three major classes of products found in nature and with great pharmacological interest 
are the coumarins, chalcones and the resveratrol derivatives. Coumarins and their 
natural and/or synthetic derivatives are pharmacologically interesting compounds due to 
their structural diversity, synthetic accessibility and substitution variability.
[1,2] 
These 
heterocyclic compounds have already been previously described as anticancer, antiviral, 
anti-inflammatory, antimicrobial, enzymatic inhibitory and antioxidant agents.
[3-18] 
Taking in account the versatility of the coumarin moiety one can thoroughly modify it 
to best serve one purposes. In this work, our group fused two other classes of natural 
products onto the coumarin skeleton, the chalcones (figure 1 - A) and the resveratrol 
derivatives (figure 1 - B). We further explored this nucleus by introducing linkers 









Figure 1 – Scheme of the different compound synthesized A – coumarin-chalcone hybrid, B – coumarin-resveratrol 
hybrid and its derivatives: C and D. By introducing a carbonyl group in B we can obtain A. 
Chalcones are widely spread in fruits, vegetables, edible plants, spices and tea and have 
been subject of study for their remarkable pharmacological activity. In addition, they are 
considered to be precursors of flavonoids and isoflavonoids.
[19] 
Resveratrol and its 
derivatives are present primarily in red wine, skin of red grapes and peanuts and present 
significant anti-oxidant activity. 
Our goal is to combine the structure of these compounds with a coumarin skeleton to 
achieve new chemical entities with extraordinary activity towards different targets, 
mostly focusing on age related diseases. This way we conducted studies of 
acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibition, proven their 
involvement in the progression of Alzheimer’s disease, monoamine oxidase A (MAO-
A) and B (MAO-B) inhibition for their importance as targets for treating Parkinson’s, 
anti-oxidant activity and cytotoxicity. The series of compounds synthesized are shown 




All together our group synthesized a total of 16 compounds and performed various 




The chemicals used in the synthesis were supplied by Aldrich and Merck. Melting 
points were determined using a Reichert Kofler thermopan or in capillary tubes on a 
Büchi 510 apparatus and are uncorrected. 
1
H NMR spectra were recorded on a Bruker 
AMX spectrometer at 250 MHz, using TMS as internal standard (chemical shifts in δ 
values, J in Hz). Silica gel (Merck 60, 230–00 mesh) was used for flash 
chromatography (FC). Analytical thin layer chromatography (TLC) was performed on 
plates precoated with silica gel (Merck 60 F254, 0.25 mm). 
 
Figure 2 – Classes of compound synthesized: A – Coumarin-chalcones derivatives; B and C – 3-amidocoumarins. 
General procedure for the preparation of coumarin-chalcone precursors (1-4)
[20] 
To a solution of 1 mmol of the appropriate β-ketoester and 1 mmol of the correspondent 
salicylaldehyde in ethanol (EtOH), in a round bottom flask with a flux of argon at 
reflux, was added catalytic amounts of piperidine. The reaction mixture was then stirred 
for 2-5 h. After completion the obtained precipitate was filtered off, washed with cold 
EtOH and purified by recrystallization with dichloromethane/methanol mixture to give 
the desired product (scheme 1). 




To 1 mmol of the corresponding methoxy-3-benzoylcoumarin, BBr3 in DCM (20 mmol, 
1M) was added in a Schlenk tube. The tube was sealed, and the reaction mixture was 
heated at 80 °C for 48 h. The resulting crude product was treated with MeOH and 
rotated to dryness. The obtained precipitate was recrystallized from MeOH or purified 
by flash chromatography using hexane/ethyl acetate mixtures as the eluent to afford the 











Scheme 1 – Preparation of coumarin-chalcone derivatives. Reagents and conditions: a) piperidine, EtOH, reflux, 2-5h; 
b) BBr3, 80 ºC, 48h, DCM. 
General procedure for the preparation of the 3-amidocoumarin derivatives (9-12) 
To a solution of 5 mmol of coumarin-3-carboxylic acid in dichloromethane (DCM), in a 
round bottom flask with a flux of argon at 0 ºC, 5.5 mmol of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and 5.5 mmol of 4-dimethylaminopyridine 
(DMAP) were added. Short after was added, in small portions, 5 mmol of the 
corresponding amine, and then the reaction mixture was stirred for 4 h at room 
temperature. The obtained precipitate was filtered and purified by recrystallization with 
ethanol or by column chromatography (hexane/ethyl acetate 9:1) to give the desired 
product (Scheme 2 - A). 
General procedure for the preparation of 3-amidocoumarin derivatives (12-16)
[21] 
To a solution of 3-aminocoumarin (1 mmol) and pyridine (1.1 mmol) in 
dichloromethane (9 mL), the corresponding acid chloride (1.1 mmol) was added 
dropwise and the reaction was stirred, at room temperature, for 3 hours. The solvent was 
evaporated under vacuum and the dry residue was purified by FC (hexane/ethyl acetate 










Scheme 2 - Reagents and conditions: a) EDC, DMAP, DCM, 0 ºC to r.t.; b) substituted acid 
chloride, pyridine, DCM, r. t., 3 h. 












3.85 (s, 3H, CH3), 7.05 (d, J= 8.8 Hz, 2H, H-3’, 
H-5’), 7.33-7.55 (m, 2H, H-6, H-7), 7.70 (d, J= 
7.26 Hz, 1H, H-8), 7.83 (d,  J= 8.6 Hz, 1H, H-






3.82 (s, 3H, OCH3), 7.09 (s, 1H, H-7), 7.14 (s, 
1H, H-5), 7.24–7.51 (m, 3H, H-3’, H-4’, H-5’), 







3.81 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.93 
(s, 3H, OCH3), 7.04 (d, J= 8.2 Hz, 1H, H-5′), 
7.27−7.43 (m, 3H, H-5, H-6, H-7), 7.46 (d, J= 
2.1 Hz, 1H, H-2′), 7.54 (dd, J= 8.2, 2.1 Hz, 1H, 






3.80 (s, 3H, 3′-OCH3), 3.85 (s, 3H, 8-OCH3), 
3.96 (s, 3H, 4′-OCH3), 7.04 (d, J= 8.5 Hz, 1H, 
H-5′), 7.46 (s, 1H, H-2′), 7.49−7.67 (m, 3H, H-






6.86 (d, J= 8.8, 2H, H-3′,H-5′), 7.37−7.51 (m, 
2H, H-6, H-8), 7.64−7.78 (m, 1H, H-7), 
7.75−7.89 (m, 3H, H-5, H-2′,H-6′),  8.30 (s, 1H, 





7.24−7.34 (m, 1H, H-8), 7.44−7.63 (m, 3H, H-
3′, H-4′, H-5′), 7.64−7.79 (m, 1H, H-5), 7.93 
(dd, J= 8.1, 1.4 Hz, 2H, H-2′, H-6′), 8.30 (s, 1H, 






6.82 (d, J= 8.2 Hz, 1H, H-5′), 7.06−7.36 (m, 
5H, H-5, H-6, H-7, H-2′, H-6′), 8.20 (s, 1H, H-
4), 9.47 (s, 1H, OH), 10.10 (s, 1H, OH), 10.35 






6.81 (dd, J= 8.1, 3.0 Hz, 1H, H-6′), 7.12−7.38 
(m, 3H, H-7, H-2′, H-5′), 7.45 (d, J= 2.2 Hz, 
1H, H-5), 8.14 (s, 1H, H-4), 9.48 (s, 1H, OH), 




7.15 (td, 1H, H-4’, J=1.1, 7.4), 7.35-7.55 (m, 
4H, H-6, H-8, H-3’, H-5’), 7.70-7.78 (m, 3H, 
H-7, H-2’, H-6’), 8.00 (dd, 1H, H-5, J=1.6,7.7), 
8.90 (s, 1H, H-4), 10.63 (s, 1H, NH). 





6.82-6-92 (m, 3H, H-8, H-4’, H-5’), 7.46-7.57 
(m, 2H, H-6, H-7), 7.76 (d, 1H, H-5, J=7.4), 
8.04 (d, 1H, H-3’, J=7.1), 8.39 (d, 1H, H-6’, 
J=7.1), 9.05 (s, 1H, H-4), 10.23 (s, 1H, OH), 
269-270 54  





6.75 (d, 2H, H-3’, H-5’ J= 7.5), 7.41-7.58 (m, 
4H, H-7, H-8, H-2’, H-6’), 7.76 (t, 1H, H-6, J= 
6.8), 8.01 (t, 1H, H-5, J= 6.8), 8.89 (s, 1H, H-






2.35 (s, 3H, CH3), 6.76-6.92 (m, 2H, H-4’, H-
5’), 7.40 (d, 2H, H-7, H-8’, J= 8.6), 7.55 (d, 1H, 
H-3’, J= 8.2), 7.77 (s, 1H, H-5), 8.35 (d, 1H, H-
6, J= 7.5), 8.92 (s, 1H, H-4), 10.18 (s, 1H, OH), 












3.83 (s, 6H, (OCH3)2), 7.09 (d, 1H, H-5’, 
J=8.46), 7.33-7.44 (m, 2H, H-6, H-6’), 7.51-
7.61 (m, 3H, H-2’, H-7, H-8) 7.74 (d, 1H, H-5, 





Ref. [16] - - 
 
Pharmacology: AChE and BuChE inhibition 
In 96-well plates, the sample was dissolved in phosphate buffer (8 mM K2HPO4, 2.3 
mM NaH2PO4, 150 mM NaCl, and 0.05% Tween 20 at pH 7.6) and an AChE/BuChE 
solution (50 μL, 0.25 unit/mL) from Electroporus electricus and equine serum, 
respectively, in the same phosphate buffer, was added. The assay solutions, except 
substrate, were pre-incubated with the enzyme for 30 min at room temperature. After 
pre-incubation, the substrate was added. The substrate solution consists of Na2HPO4 (40 
mM), acetylthiocholine/butyrylthiocholine (0.24 mM) and 5,5′-dithio-bis-(2-
nitrobenzoic acid) (0.2 mM, DTNB, Ellman’s reagent). Absorbance of the yellow anion 
product, due to the spontaneous hydrolysis of substrate, was measured at 405 nm for 5 
min on a microtiter plate reader (Multiskan EX, Thermo, Vantaa, Finland). The 
AChE/BuChE inhibition was determined for each compound. The enzyme activity was 
calculated as a percentage compared to a control using only the buffer and enzyme 
solution. The compounds were assayed in the dilution interval of 500 to 15 μg/mL, and 
the alkaloid galanthamine was used as the reference compound. Each assay was run in 
triplicate and each reaction was repeated at least three independent times. The IC50 
values were calculated by means of regression analysis.
[21] 
Pharmacology: MAO-A and MAO-B inhibition 
Briefly, 0.1 mL of sodium phosphate buffer (0.05 M, pH 7.4) containing various 
concentrations of the test drugs (new compounds or reference inhibitors) and adequate 
amounts of recombinant hMAO-A or hMAO-B required and adjusted to obtain in our 
experimental conditions the same reaction velocity, i.e., to oxidize (in the control group) 
165 pmol of p-tyramine/min (hMAO-A: 1.1 g protein; specific activity: 150 nmol of p-
tyramine oxidized to p-hydroxyphenylacetaldehyde/min/mg protein; hMAO-B: 7.5 g 
protein; specific activity: 22 nmol of p-tyramine transformed/min/mg protein) were 
incubated for 15 min at 37 ºC in a flat-black-bottom 96-well microtest
 
plate (BD 
Biosciences,  Franklin Lakes, NJ, USA) placed in the dark multimode microplate reader 
chamber. After this incubation period, the reaction was started by adding (final 
concentrations) 200 μM Amplex Red reagent, 1 U/mL horseradish peroxidase and 1 
mM p-tyramine. The production of H2O2 and, consequently, of resorufin was quantified 
at 37 °C in a multi-mode microplate reader (Fluostar Optima, BMG Labtech GmbH, 
Offenburg, Germany), based on the fluorescence generated (excitation, 545 nm, 
emission, 590 nm) over a 15 min period, in which the fluorescence increased linearly. 
Control experiments were carried out simultaneously by replacing the test drugs (new 
compounds and reference inhibitors) with appropriate dilutions of the vehicles. In 
addition, the possible capacity of the above test drugs to modify the fluorescence 
generated in the reaction mixture due to non-enzymatic inhibition (e.g., for directly 
reacting with Amplex
 
Red reagent) was determined by adding these drugs to solutions 
containing only the Amplex
 
Red reagent in a sodium phosphate buffer. 
To determine the kinetic parameters of hMAO-A and hMAO-B (Km and Vmax), the 
corresponding enzymatic activity of both isoforms was evaluated (under the 
experimental conditions described above) in presence of a number (a wide range) of p-
tyramine concentrations. 
The specific fluorescence emission (used to obtain the final results) was calculated after 
subtraction of the background activity, which was determined from vials containing all 
components except the MAO isoforms, which were replaced by a sodium phosphate 
buffer solution. 
 
Pharmacology: anti-oxidant activity 
To the corresponding coumarin−chalcone hybrid compound (1.2 mmol) in dimethyl 
sulfoxide (20 μL), a hydrogen peroxide solution (50 μL, 30%) and a sodium hydroxide 
solution (50 μL, 25 mM) were added. The total volume of the resulting solution (300 
μL) was completed with DMSO to achieve a final 4 mM solution of the tested 
compounds.  
The ORAC-FL assays were carried out on a Synergy HT multidetection microplate 
reader (Bio-Tek Instruments, Inc.) using white polystyrene 96-well plates. Fluorescence 
was read from the top, with an excitation wavelength of 485/20 nm and an emission 
filter of 528/20 nm. The plate reader was controlled by Gen 5 software. The oxygen 
radical absorbance capacity was determined as previously described46 with slight 
modifications. The reaction was carried out in 75 mM sodium phosphate buffer (pH 7.4) 
at a 200 μL final volume. FL (70 nM, final concentration) and coumarin−chalcone 
solutions in methanol with a range of concentration between 0.3 to 2 μM and 0.5 to 7 
μM for the monohydroxy and dihydroxy derivatives, respectively, were placed in each 
well of the 96-well plate. This range of concentration was selected empirically to obtain 
a good separation between the fluorescence curves. This separation was crucial for more 
accurate data treatment. The mixture was preincubated for 15 min at 37 °C before 
rapidly adding the AAPH solution (18 mM, final concentration). The microplate was 
immediately placed in the reader and automatically shaken prior to each reading. The 
fluorescence was recorded every 1 min for 120 min. A blank with FL and AAPH using 
methanol instead of the antioxidant solution as well as five calibration solutions using 
Trolox (0.5 to 2.5 μM) as a standard molecule were also used in each assay. The 
inhibition capacity was expressed as ORAC values, and it was quantified by employing 
eq 1. All reaction mixtures were prepared in triplicate, and at least three independent 
assays were performed for each sample. 
                   
            
              
        




 = area under the curve blank; AUC = area under the curve derivative; 
AUCtrolox = area under the curve, Trolox (standard); [trolox] = Trolox concentration, 
molar; and [derivative] = derivative concentration, molar.  
The AUC was calculated by integrating the decay of the fluorescence where F0 is the 
initial fluorescence read at 0 min and F is the fluorescence read at a particular time. The 
AUCNET corresponding to the sample was calculated by subtracting the AUC 
corresponding to the blank. Data processing was performed using Origin Pro 8 SR2 
(Origin Lab Corporation). Antioxidant Reactivity by ESR Assay. The reactivity of all 
coumarin−chalcone hybrids against hydroxyl radicals was assessed using the 
noncatalytic Fenton method that was previously described.56 In a typical experiment, 
150 μL of dimethyl sulfoxide was mixed with 50 μL of NaOH (3 mM) followed by the 
addition of 50 μL of DMPO (30 mM) spin trap and 50 μL of hydrogen peroxide (30%). 
All derivatives were studied at a 4 mM final concentration and a 300 μL final volume. 
The mixture was positioned in the ESR cell, and the spectra were recorded after 5 min 
of the reaction. 
Pharmacology: cytotoxicity and cytoprotection assays 
Cytotoxicity assays in BAEC cells were performed for all coumarin−chalcone hybrids 
using the MTT reduction assay. BAEC were seeded in 24-well plates at a density 
ranging between 104 −105 cells/mL per well. After the cells reached 60−70% 
confluence, they were incubated in the presence of 10 to 50 μM of the corresponding 
coumarin−chalcone derivatives for 24 h. After incubation, the medium was changed (2 
mL) and 45 μL of a solution of MTT (5 mg/mL in DMEM supplemented with 0.5% 
FBS) was added to each well. The cells were incubated for another 2 h at 37 °C. The 
medium was then removed, and the wells were rinsed once with PBS. DMSO (0.6 mL) 
was added to each well at room temperature to solubilize the formazan crystals. The 
dissolved formazan was then transferred into 96-well culture plates, and the absorbance 
was measured at 570 nm using a UV-vis spectrometer. The percent of inhibition of cell 
viability was calculated using eq 2 percent inhibition (1 / 100) = − A A t s (2) where At 
and As are the absorbance of the sample solution and the solvent alone, respectively. To 
assess the cytoprotective properties of the compounds against H2O2 and SIN-1, BAEC 
(104 −105 cells/mL) were grown to 60−70% confluence in 24-well plates and each well 
was incubated with the selected derivative at 10 and 20 μM concentrations for 24 h. 
After incubation, the cells were washed with 1× PBS twice to remove the residual drug 
and exposed to 1 mM of H2O2 and 500 μM of SIN-1 for 2 h and 4 h, respectively. These 
time periods were chosen on the basis of the observed cell death (>50%) using the H2O2 
and SIN-1 concentrations mentioned above. Finally, cell viability was evaluated by the 
MTT reduction assay and calculated using eq 2. Statistical Analysis. The experimental 
results are expressed as the mean ± standard error of the mean (SEM) and are 
accompanied by the number (n) of observations. The differences between the groups 
were analyzed by student’s t test. 
Results and Discussion 
In the present work we exploit the synthesis and pharmacological activity of a series of 
coumarin derivatives (figure 1). With the aim to mimic some of the structural functions 
of already natural products, we explored the importance of the nature of different 
spacers in the position 3 of the coumarin scaffold and some small groups (methyl, 
methoxy, hydroxyl, bromo and chloro) attached to the benzenic ring. Our coumarin 
derivatives 1-16 were efficiently synthesized and characterized (Table 1). We started 
from the commercially available products, and obtained different derivatives in 
moderate to excellent yields. Our compounds were tested according the protocols 
previously reported, and we achieved promising results. In this paper we present some 
of those results (table 2, 3 and 4). 
Table 2 - ORAC values and percentage of radicals scavenging for compounds 5-8 as measured by ESR spin trapping 
in competition with DMPO. 
Compound ORAC-value % radical scavenging 
5 9.2 ± 0.4 26 
6 8.3 ± 0.3 65 
7 8.1 ± 0.6 75 
8 8.8 ± 0.5 100 
Trolox 1.0 ± 0.2 31 
Quercetin 7.3 ± 0.2 N.D. 
Catechin 6.8 ± 0.2
 
N.D. 
N. D. – non determined. 
 
Table 3 - Cytotoxicity of compounds 5-8 tested at three different concentrations on BAEC. Results are expressed on 
percentage (%) of cell viability (n = 3). 
Compound 10 µM 20 µM 50 µM 
5 76 ± 7 60 ± 6 44 ± 5 
6 96 ± 3 101 ± 1 93 ± 4 
7 49 ± 2 68 ± 2 63 ± 2 
8 64 ± 2 23 ± 2 71 ± 6 
 
Table 4 – IC50 values for the compounds 9-16 and reference compounds on the enzymatic activity of human 










9 N.D. N.D. 565.93 ± 0.01 N.A. 
10 N.D. N.D. 284.09 ± 0.13 N.A. 
12 N.D. N.D. 666.37 ± 0.11 N.A 
13 >100 0.76 ± 0.05 N.A N.A 
14 >100 30.50 ± 2.06 69.47 ± 4.65 N.A 
15 >100 58.38 ± 3.91 N.A N.A 
16 >100 1.95 ± 0.13 18.71 ± 0.84 N.A 
Seligiline 68.73 ± 4.21 0.017 ± 0.0019 - - 
Eserine - - 0.10 ± 0.03 0.15 ± 0.02 
N. D. – non determined, N.A. – non active. 
Conclusions 
In this work, we describe the synthesis of different scaffolds of natural-hybrid 
compounds by employing different reactions settings. We successfully obtained 16 
compounds in good to excellent yields. The electrochemical properties of the studied 
compounds proved to be excellent, presenting low oxidation potentials, very high 
ORAC values (higher than the reference compounds quercetin and catechin), and a high 
percentage of radical scavenging. The compounds presented low cytotoxicity for BAEC 
in culture, mainly compound 6 with 93% cell viability in the highest concentration 
tested. 
With the enzymatic inhibition assays we could determine the IC50 values of our 
compounds and found that compound 13 is selective for MAO-B and has the best IC50 
of all the compounds tested. However, the interesting part is that some compounds were 
found to have dual activity against both MAO-B and AChE, making them potential 
candidates to a lead compound and a more thorough future study. 
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